Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC

NCT05910034 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

132

Enrollment

OTHER

Sponsor class

Conditions

Advanced Non-Small Cell Lung Cancer

Interventions

DRUG: Trilaciclib+Envafolimab+Docetaxel
DRUG: Envafolimab+Docetaxel
DRUG: Docetaxel

Sponsor

Fudan University